the individualized patient-management strategies in developed countries, based on routinely available diagnostic monitoring. 7 Standardized first-line ART regimens consist of a non-nucleoside reverse transcriptase inhibitor (NNRTI) and a dual nucleoside/ nucleotide reverse transcriptase inhibitor (NRTI) backbone, available in some countries as generic fixed-dose combinations. 6 Recommended second-line regimens combine a ritonavir-boosted protease inhibitor (PI) with two previously unused and/or recycled NRTIs. 6 Routine HIV viral-load monitoring is not generally available in resource-limited countries and treatment failure is frequently identified based on immunological definitions and/or the occurrence of clinical events. 6 Virological breakthrough may be detected late while the failing regimen is continued, thus facilitating the acquisition and accumulation of drug resistanceassociated mutations. 8 Drug-resistant HIV variants may compromise the effectiveness of subsequent lines of treatment and their transmission to newly infected individuals has severe public health consequences. 9, 10 To date, ART programmes have been implemented without accompanying HIV drug resistance (HIVDR) monitoring. Monitoring studies are hampered by the lack of a molecular laboratory infrastructure required for genotypic resistance testing, logistical challenges related to maintaining specimen integrity in remote settings and the high costs of testing. 11 Challenges to scaling up ART in resource-limited countries, such as absence of routine virological monitoring and limited choices of drug regimen, advocate for the development of a global public-health framework to monitor and prevent the emergence of HIVDR and thus maximize long-term ART effectiveness. 12 HIV-1 subtype B is the predominant viral subtype in North America, Western Europe and Australia, and antiretroviral (ARV) drugs have been developed on this subtype. However, in sub-Saharan Africa and Asia, the genetic diversity in HIV subtypes and circulating recombinant forms (CRFs), resulting from recombination between subtypes within a dually infected person, is extensive. 13 Although current evidence is limited, some reports have suggested that the propensity to develop HIVDR and the spectrum of mutations that emerge during drug selective pressure, may differ across subtypes and CRFs.
14-17 Viral heterogeneity may, therefore, have implications for rates of disease progression and patient response to ART, warranting further study of inter-subtype differences in mutational pathways to resistance.
To help assess the extent of HIVDR in sub-Saharan Africa and Asia, a collaborative bi-regional programme was established, called LAASER [Linking African and Asian Societies for an Enhanced Response (LAASER) to HIV/AIDS; http://www.laaser-hivaids.org] with the primary aim of increasing regional capacities for the monitoring of HIVDR. PharmAccess Foundation, a non-profit organization dedicated to the strengthening of health systems and improving access to quality basic health care in sub-Saharan Africa, has developed the PharmAccess African Studies to Evaluate Resistance (PASER). TREAT Asia (Therapeutics, Research, Education and AIDS Training in Asia) is a network of clinics, hospitals and research institutions working to ensure safe and effective delivery of HIV/AIDS treatment throughout the Asia-Pacific and has developed the TREAT Asia Studies to Evaluate Resistance (TASER). Both PASER and TASER programmes incorporate a monitoring and evaluation (M) and a surveillance (S) protocol. Laboratories providing genotyping results for PASER and TASER are required to participate in the TREAT Asia Quality Assurance Scheme (TAQAS), which is an ongoing assessment programme to build genotyping laboratory capacity, described elsewhere. 18 The focus of this cohort profile is the monitoring and evaluation protocols, PASER-M and TASER-M.
How are PASER and TASER set up and how are they funded? Figure 1b . ART has been available in Asia for more than 10 years, even in less-resourced countries in the region, and all TASER-M clinical sites have on-site viral load testing.
Clinical sites follow their national guidelines to assess eligibility for ART initiation in accordance with the WHO recommendations. 6 Genotypic resistance testing on PASER and TASER clinical specimens are performed in TAQAS-certified genotyping laboratories. 18 Laboratories are encouraged to become accredited members of the WHO/HIVResNet HIV Drug Resistance Laboratory network. 21 Population-based nucleotide sequencing of the HIV protease (PR) and partial reverse transcriptase (RT) gene regions is performed on plasma specimens, which have HIV RNA of more than 1000 copies/ml. Plasma is obtained from blood collected in EDTA tubes which is locally stored at À808C and, if required, batch-shipped on dry ice to a genotyping laboratory.
PASER-M genotypic testing is concentrated in two central reference laboratories and thus depends on a robust cold-chain and web-based specimen tracking system for managing specimen shipments. Approximately half of TASER-M clinical sites have an on-site or local genotyping laboratory. Most genotyping laboratories amplify viral sequences using in-house methods, based on assembled commercially available assay components and laboratory-specific sequencing and amplification primers. One TASER laboratory uses the commercial kit TruGene (Bayer HealthCare, Tarrytown, NY, USA). The online Stanford interpretation system is used by most laboratories to identify drug resistance-associated mutations. 22 Resistance genotyping is generally performed retrospectively (i.e. not real-time) for all participants. Details of the genotyping laboratories are summarized in Supplementary Table 2 available as Supplementary data at IJE online. PASER and TASER sequences are submitted to the ViroScore database (Advanced Biological Laboratories SA, France) for data storage.
What do PASER-M and TASER-M cover and who is included in the sample?
The monitoring studies are multi-centre prospective cohort designs with sequential patient enrolment. Patient eligibility criteria are listed in Table 1 . The main study objectives are to assess prevalence and incidence of HIVDR, mutational patterns and factors associated with HIVDR in persons initiating first-line ART or switching to a second-line regimen due to treatment failure under routine circumstances. Participants are required to sign informed consent prior to study enrolment and must initiate or switch ART within 30 days (PASER-M) or 181 days (TASER-M) following baseline specimen collection. Regimen switch due to treatment failure may be determined clinically, as assessed by disease progression, immunologically, by CD4 cell count or virologically, by HIV viral load. A single drug substitution, due to toxicity or intolerance, is not considered a regimen switch. Each site aims to recruit a total of 240 participants. Second-line participants are recruited among first-line participants failing therapy and the clinical site patient population. The recommended maximum site-specific enrolment period is 18 months.
How often are participants followed-up? What data are being collected?
Participants are followed-up as per local standard of care guidelines. The frequency of follow-up visits for patients varies by site (range: every 1-6 months). The studies make use of clinical data collected during routine visits and recorded in medical records. HIV viral load measurement and, if the HIV RNA value is more than 1000 copies/ml, genotypic resistance testing is performed on plasma specimens taken at baseline, prior to regimen switch due to treatment failure and at annual follow-up. For patients failing a first-line regimen, the treatment failure data collection becomes the new baseline for the second-line regimen. Annual follow-up is then calculated from this point. For patients failing a second-line ART, the treatment failure data collection is the final assessment prior to the patient going off study.
PASER-M clinical data are recorded on standardized hard-copy data forms, which are completed at 3-monthly intervals and entered in a web-based clinical data system, called the HAART Monitoring System. PharmAccess performs quality assurance measures, which include (i) source data verification during 3-to 6-monthly site audits, (ii) checks to identify data entry inconsistencies or suspect data values and (iii) specimen tracking. TASER-M site personnel extract clinical data from site databases and medical PASER AND TASER MONITORING Figure 1 Geographical location of (a) PASER-M collaborating sites and (b) TASER-M collaborating sites records collected as part of usual care. From March 2008 to March 2009, TASER-M data were submitted electronically to NCHECR on a quarterly basis, as part of study start up, then at 6-monthly intervals. At each transfer, NCHECR performs quality assurance measures, which include (i) checks to identify data entry inconsistencies or suspect data values, (ii) specimen tracking and (iii) ARV history completeness. Annually, a random 10% of TASER-M patients are selected for internal site audit where submitted data are compared with patient medical records.
The studies capture standardized virological and genotypic data at protocol determined intervals. Genotyping data consist of HIV subtype and HIVDR mutations, including insertions and deletions. TASER-M also records discordant subtypes, i.e. when the PR and RT region subtypes differ. Laboratory specimen tracking information is recorded during specimen processing, allowing assessment of pre-analytical and assay validity. Genotyping laboratories complete an annual laboratory survey that includes the dynamic range of the virological assay used, the regions of PR and RT genome routinely sequenced and the interpretation algorithm used. Observational patient data includes demographic parameters, physical measures, Centres for Disease Control and Prevention (CDC) class (TASER-M) or WHO clinical stage (PASER-M), serology of hepatitis and syphilis (TASER-M), opportunistic infections, current ART regimen, ARV history, concomitant medications, routine laboratory parameters (including CD4 counts) and assessment of drug adherence. Main analyses will include age, sex, ethnicity, HIV exposure category, WHO clinical stage (PASER-M) or CDC class (TASER-M), viral hepatitis co-infection status, CD4 count, HIV viral load, HIV subtype, drug adherence, ARV history and ART regimen as covariates. Predictors of drug resistance will be assessed using logistic regression models. Incidence of drug resistance will be summarized using person-years methods and Kaplan-Meier plots. Cox proportional hazards models will be used to assess risk factors associated with developing drug resistance.
What is the anticipated attrition?
The actual attrition in PASER-M and TASER-M cannot currently be accurately estimated because the duration of follow-up in the databases is still limited. In sub-Saharan Africa patient retention in routine ART programmes has been estimated at 61. 6 23 to 66.8% 2 at 24 months on ART, attrition being mainly due to loss of follow-up and early death. 23 Therefore, in PASER-M, the original site-specific sample size was calculated accounting for 20% loss to follow-up and 25% mortality after 24 months. Attrition is expected to vary between sites as a result of differences in patient populations, care provided and provisions for tracing lost to follow-up. TASER-M sites are generally sourced from the ongoing TREAT Asia HIV Observational Database (TAHOD). 19 Loss to follow-up for TAHOD was 6.9/100 person-years for the 12-month period from September 2007 to September 2008. Since TASER-M monitors specified outcomes, we speculate that TASER-M follow-up will be similar to TAHOD or better.
What has been found? PASER-M Patient recruitment commenced in March 2007 and was completed in September 2009. Of the 13 sites, 12 reached the site-specific target of 240 participants, enrolling a total of 3005 participants. Excluding patients with protocol violations (n ¼ 16) and key data missing (n ¼ 4), 2985 patients were included in the analysis. Of these, 2736 (91.6%) were eligible for a first-line ART regimen and 249 (8.3%) were eligible for second-line ART due to treatment failure. Patient characteristics are summarized in Table 2 . For first-line patients, the median age was 36.8 years [inter-quartile range (IQR) 31.3-42.6] and 58% were women. HIV exposure was predominantly reported as heterosexual contact. More than 60% had advanced disease (classified as WHO stages III or IV) and 37% had pre-therapy CD4 counts of less than 100 cells/ml. Across all 13 sites, median baseline CD4 counts of The most frequently prescribed first-line regimens were based on NNRTIs (99.7%), i.e. efavirenz (EFV) and nevirapine (NVP) at 60 and 40%, respectively. First-line dual NRTI backbones were predominantly lamivudine (3TC)/zidovudine (AZT) (37%), emtricitabine (FTC)/tenofovir (TDF) (34%) and 3TC/stavudine (d4T) (26%). Overall, 67% of patients started a 3TC-containing first-line regimen. Among patients initiating first-line ART, 95% (n ¼ 2 598) reported to be ARV-naive and 5% (n ¼ 138) had previous ARV experience, which included ART (n ¼ 60), mono/dual therapy (n ¼ 6), single-dose NVP for prevention of mother-to-child transmission of HIV (PMTCT) (n ¼ 35), combination therapy for PMTCT (n ¼ 19), and unspecified (n ¼ 22). Compared with ARV-naive first-line patients, ARV-experienced first-line patients had higher median CD4 counts (177 vs 133 cells/ml, P < 0.0001), were younger (median 34.7 vs 37.0 years, P < 0.0001) and were more likely to be female (76.1 vs 57.5%; P < 0.001). Other baseline characteristics did not differ between ARV-naive and ARV-experienced patients. For the 249 (8.3%) patients switching to second-line ART, the median age was 38.6 years (IQR 32.9-44.2) and sex was equally distributed. HIV exposure was predominantly heterosexual contact and 48% of patients had advanced disease (classified as WHO stages III or IV). Median CD4 count was 125 cells/ml . Median pre-switch HIV viral load was 4.1 log 10 copies/ ml (IQR 3.2-5.0). Ritonavir-boosted lopinavir (LPV) was the PI used almost exclusively (98%).
As shown in Table 3 , analysis of the first available 1795 viral sequences demonstrated that the most common HIV subtypes in the cohort were C (1216, 68.7%), A (338, 18.7%) and D (179, 10.0%). The first PASER report published in 2008 reviewed the available data on HIVDR in sub-Saharan Africa.
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Baseline HIVDR data from Lusaka, Zambia, has recently been published. 24 International presentations have summarized preliminary baseline HIVDR mutations and subtype distributions. Table 2 . For ARV-naive first-line patients, the median age was 36.5 years. Almost two-thirds of patients were male and HIV exposure was predominantly heterosexual contact. More than one-third of patients were classified as CDC class C and almost half of the patients had pre-therapy CD4 counts less than 100 cells/ml. Median baseline HIV viral load was 5.0 log 10 copies/ml (IQR 5. 4-6.8) and the most common first-line regimens were based on NNRTIs (85.6%). Excluding 14 (2.4%) patients on a randomized clinical trial with a blinded NNRTI 4-41.9) . Females were in the majority (64%), HIV exposure was predominantly heterosexual (92%) and 60% of patients had experienced at least one CDC class C event. Of 21 patients with CD4 counts available within 6 months of starting a second-line therapy, the median CD4 count was 197 (IQR 109-299). Median pre-switch HIV viral load was 4.0 log 10 copies per/ml (IQR 3.6-4.5). All patients were on PI-based regimens, following failure on first-line NNRTI-based regimens (median duration 30.3 months). The most commonly prescribed PI component was ritonavir-boosted LPV (88%).
As shown in Table 3 , from analysis of the 728 available viral sequences, the most common subtypes were CRF01_AE (584, 80.2%) and subtype B (111, 15.2%). Non-CRF01_AE recombinants were identified in eight (1.1%) patient specimens. For 21 (2.9%) specimens, the subtype differed between PR and RT regions, suggesting dual infection or recombination. International presentations have summarized 2009 baseline HIVDR mutations and subtype distributions. 27, 28 Complete baseline and prospective outcome data for PASER-M and TASER-M are anticipated to become available in 2010-13. What are the main strengths and weaknesses?
Programmes that monitor national and regional levels of primary and secondary HIVDR contribute to evidence-based recommendations to inform treatment guidelines and provide feedback on the success of HIV treatment and prevention programmes. PASER and TASER, with TAQAS, are developing capacity in sub-Saharan Africa and the Asia-Pacific for coordinated HIVDR monitoring and genotypic laboratory testing. The study protocols are harmonized with the WHO HIV Drug Resistance Prevention Survey protocol. 29 An important strength is the large number of patients and sites participating, representing a diverse spectrum of patient populations, clinic types, ART regimens and HIV subtypes. Opportunities exist to investigate the impact of drug resistance on HIV natural history, rates of disease progression and response to treatment in non-B subtypes. Data from genotypic resistance testing will also provide insight into the population genetics and dynamics of transmitted HIVDR in the region.
PASER-M and TASER-M have several limitations. First, patient samples at each site are not necessarily representative of the site, country or region. Second, data quality depends on the completeness of clinical information captured through routine patient care. In PASER-M, data may have been collected under varying conditions, since some sites had no or limited research experience at study initiation. Third, at some sites, study initiation was delayed by several months due to the time required for contract negotiation, IRB study approval and, in TASER-M, procurement of FWAs. After study initiation, recruiting the required number of patients within the recommended 18-month period proved difficult for some sites, due to asymptomatic patients not seeking care or treatment, cost of medication or low-prevalence in their setting. Fourth, HIVDR monitoring activities in resource-limited countries in sub-Saharan Africa are limited by high costs of laboratory testing. To address this challenge, PASER has initiated a public-private consortium, called Affordable Resistance Test for Africa (ART-A), which aims to develop affordable test algorithms for the detection and interpretation of HIVDR for use in laboratories and clinics (http:// www.arta-africa.org).
How can I collaborate? Where can I find out more?
Ownership of individual site data remains with the contributing site. Sites are represented by their principal investigators on the respective PASER and TASER Steering Committees. Research is to be the subject of peer-reviewed publications and analysis priorities are driven by a concept sheet process. Both studies accept concept proposals from external researchers for review, if submitted in collaboration with one or more of the site principal investigators. The PASER and TASER protocols contribute data under the LAASER partnership (http://www.laaser hivaids.org) and TASER also contributes data to IeDEA. 20 Collaborating sites are also encouraged to make an appropriate subset of their data available to Ministry of Health in their respective countries in order to contribute to local efforts in monitoring HIVDR. Questions regarding participation, research concepts or requests for data should be sent to Tobias Rinke de Wit, email: t.rinkedewit@ pharmaccess.org (PASER), or Thida Singtoroj, email: thida.singtoroj@treatasia.org (TASER). The funders had no role in the study design, data collection, data analysis, data interpretation, decision to publish or writing of the report. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.
